|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO006972225 |
| 003 |
DE-627 |
| 005 |
20230425180744.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2017 xx |||||o 00| ||dan c |
| 035 |
|
|
|a (DE-627)WHO006972225
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2007-004791-39-DK
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)57019085
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a dan
|
| 245 |
1 |
0 |
|a Et prospektivt randomiseret fase II studie til evaluering af Gabapentin og Venlafaxin´s virkning mod hedestigninger hos kvinder opereret for brystkræft og iantihormonbehandling i form af aromatasehæmmer
|b Et prospektivt randomiseret fase II studie til evaluering af Gabapentin og Venlafaxin´s virkning mod hedestigninger hos kvinder opereret for brystkræft og iantihormonbehandling i form af aromatasehæmmer
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 05-03-2008, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Patients in adjuvant aromatase inhibitor treatment for breast cancer having serious side effects conserning hot flashes affecting daily life.
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2017) vom: 21. Aug.
|
| 773 |
1 |
8 |
|g year:2017
|g day:21
|g month:08
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004791-39
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2017
|b 21
|c 08
|
Klinische Studie